Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Importance of vaccine action and availability and epidemic severity for delaying the second vaccine dose

L. Berec, R. Levínský, J. Weiner, M. Šmíd, R. Neruda, P. Vidnerová, G. Suchopárová

. 2022 ; 12 (1) : 7638. [pub] 20220510

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22018438

Following initial optimism regarding potentially rapid vaccination, delays and shortages in vaccine supplies occurred in many countries during spring 2021. Various strategies to counter this gloomy reality and speed up vaccination have been set forth, of which the most popular has been to delay the second vaccine dose for a longer period than originally recommended by the manufacturers. Controversy has surrounded this strategy, and overly simplistic models have been developed to shed light on this issue. Here we use three different epidemic models, all accounting for then actual COVID-19 epidemic in the Czech Republic, including the real vaccination rollout, to explore when delaying the second vaccine dose by another 3 weeks from 21 to 42 days is advantageous. Using COVID-19-related deaths as a quantity to compare various model scenarios, we find that the way of vaccine action at the beginning of the infection course (preventing infection and symptoms appearance), mild epidemic and sufficient vaccine supply rate call for the original inter-dose period of 21 days regardless of vaccine efficacy. On the contrary, for the vaccine action at the end of infection course (preventing severe symptoms and death), severe epidemic and low vaccine supply rate, the 42-day inter-dose period is preferable, at any plausible vaccine efficacy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018438
003      
CZ-PrNML
005      
20220804134753.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-022-11250-4 $2 doi
035    __
$a (PubMed)35538118
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Berec, Luděk $u Department of Mathematics, Faculty of Science, Centre for Mathematical Biology, University of South Bohemia, Branišovská 1760, 37005, České Budějovice, Czech Republic. lberec@prf.jcu.cz $u Department of Ecology, Biology Centre, Institute of Entomology, The Czech Academy of Sciences, Branišovská 31, 37005, České Budějovice, Czech Republic. lberec@prf.jcu.cz
245    10
$a Importance of vaccine action and availability and epidemic severity for delaying the second vaccine dose / $c L. Berec, R. Levínský, J. Weiner, M. Šmíd, R. Neruda, P. Vidnerová, G. Suchopárová
520    9_
$a Following initial optimism regarding potentially rapid vaccination, delays and shortages in vaccine supplies occurred in many countries during spring 2021. Various strategies to counter this gloomy reality and speed up vaccination have been set forth, of which the most popular has been to delay the second vaccine dose for a longer period than originally recommended by the manufacturers. Controversy has surrounded this strategy, and overly simplistic models have been developed to shed light on this issue. Here we use three different epidemic models, all accounting for then actual COVID-19 epidemic in the Czech Republic, including the real vaccination rollout, to explore when delaying the second vaccine dose by another 3 weeks from 21 to 42 days is advantageous. Using COVID-19-related deaths as a quantity to compare various model scenarios, we find that the way of vaccine action at the beginning of the infection course (preventing infection and symptoms appearance), mild epidemic and sufficient vaccine supply rate call for the original inter-dose period of 21 days regardless of vaccine efficacy. On the contrary, for the vaccine action at the end of infection course (preventing severe symptoms and death), severe epidemic and low vaccine supply rate, the 42-day inter-dose period is preferable, at any plausible vaccine efficacy.
650    12
$a COVID-19 $x epidemiologie $x prevence a kontrola $7 D000086382
650    _2
$a vakcíny proti COVID-19 $7 D000086663
650    _2
$a lidé $7 D006801
650    _2
$a SARS-CoV-2 $7 D000086402
650    _2
$a vakcinace $7 D014611
650    12
$a vakcíny $7 D014612
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Levínský, René $u CERGE-EI, Politických vězňů 7, 11121, Prague 1, Czech Republic
700    1_
$a Weiner, Jakub $u Siesta Labs, Konopišťská 16, 10000, Prague 10, Czech Republic
700    1_
$a Šmíd, Martin $u The Czech Academy of Sciences, Institute of Information Theory and Automation, Pod Vodárenskou věží 4, 18200, Prague 8, Czech Republic
700    1_
$a Neruda, Roman $u The Czech Academy of Sciences, Institute of Computer Science, Pod Vodárenskou věží 2, 18200, Prague 8, Czech Republic
700    1_
$a Vidnerová, Petra $u The Czech Academy of Sciences, Institute of Computer Science, Pod Vodárenskou věží 2, 18200, Prague 8, Czech Republic
700    1_
$a Suchopárová, Gabriela $u The Czech Academy of Sciences, Institute of Computer Science, Pod Vodárenskou věží 2, 18200, Prague 8, Czech Republic
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 12, č. 1 (2022), s. 7638
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35538118 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134747 $b ABA008
999    __
$a ok $b bmc $g 1822160 $s 1169681
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 12 $c 1 $d 7638 $e 20220510 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options